Evidence map›Paper›PMID 35285173›Full record

Trial reportJournal of diabetes investigation2022

A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.

Yutaka Seino, Hideaki Miyoshi, Heidrun Bosch Traberg, T V S Divyalasya, Keiji Nishijima, Yasuo Terauchi

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02505334. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02505334 phase3completed

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus

Ran2015Enrolled635Registered outcomes61Posted comparisons1ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Yutaka SeinoKansai Electric Power Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0002-1099-7989
Hideaki MiyoshiDivision of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.ORCID https://orcid.org/0000-0002-5909-3243
Heidrun Bosch TrabergNovo Nordisk A/S, Søborg, Denmark.
T V S DivyalasyaNovo Nordisk Service Centre India Private Ltd, Bangalore, India.
Keiji NishijimaNovo Nordisk Pharma Ltd, Tokyo, Japan.
Yasuo TerauchiDepartment of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Novo Nordisk (Denmark) · DKHokkaido University · JPKansai Electric Power (Japan) · JPNovo Nordisk (India) · INYokohama City University · JP

Funding

Novo Nordisk A/S
6 · The paper itself

Abstract

AIMS/

introductionThe present trial compared the efficacy and safety of once-daily liraglutide 1.8 mg with liraglutide 0.9 mg in Japanese patients with type 2 diabetes to assess the incremental effects of liraglutide 1.8 mg in those who exhibited an inadequate response to 0.9 mg. MATERIALS AND

methodsThis 26-week randomized trial (NCT02505334) enrolled Japanese adults with type 2 diabetes across 47 sites in Japan. Participants with glycated hemoglobin (HbA

resultsAfter 26 weeks of treatment, liraglutide 1.8 mg was more effective compared with 0.9 mg in lowering HbA

conclusionsLiraglutide 1.8 mg had better efficacy in improving HbA

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsLiraglutideAdultBlood GlucoseDrug Therapy, CombinationGlycated HemoglobinHumansJapanTreatment OutcomeBlood GlucoseGlycated HemoglobinHypoglycemic AgentsLiraglutideGlucagon-like peptide-1LiraglutideType 2 diabetes mellitus

Identifiers

PMID35285173
PMCPMC9340870
OpenAlexW4220871444

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.